Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)

Hannover Medical School (MHH)

Status: Terminated

Conditions: Secondary Sclerosing Cholangitis

Treatments: Procedure: Endoscopic retrograde cholangiography (ERC)

Study type: Interventional

Funder types: Other

Identifiers

NCT05396755

BISCIT

Details and patient eligibility

About

This is a randomized, open-label, controlled, parallel group, multicenter clinical trial. Patients with confirmed secondary sclerosing cholangitis (SSC-CIP) will be randomized either in the intervention group undergoing scheduled invasive evaluation of the biliary tract or in the control group treated with non-interventional standard of care to demonstrate that programmed endoscopic therapy compared to a conservative strategy reduces the occurrence of treatment failures.

Enrollment: 1 patient

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients have to fulfill all of the following inclusion criteria to be eligible for participation in this study:

1. Men, women*, inter/divers, age ≥18 and ≤ 80 years (conscious or unconscious patients may be included)

2. Signed written informed consent obtained by patient or legal representative in case of unconscious patient

3. Willingness to comply with treatment and follow-up procedures

4. Suspected SSC-CIP = episode of critical illness and intensive care unit treatment > 3 days within last 12 months

5. SSC-CIP is confirmed by ERC, (if the first ERC is performed at baseline, the patient may be considered as screening failure if the diagnosis is not confirmed)

6. Elevation of bilirubin ≥ 2.5 upper limit of normal (ULN) at Screening

7. Elevation of alkaline phosphatase (AP) or gamma-glutamyl-transferase (GGT) > 2.5 ULN or elevation of both at Screening

8. *Women without childbearing potential defined as follows:

   • at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or

   • hysterectomy or uterine agenesis or

   • ≥ 50 years and in postmenopausal state > 1 year or

   • < 50 years and in postmenopausal state > 1 year with serum Follicle Stimulating Hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or

     *Women of childbearing potential:

   • who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or

   • who have sexual relationships with female partners only and/or with sterile male partners or

   • who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception (failure rate of < 1% per year) from the time of screening until end of the clinical trial.

Exclusion criteria

1. Patient is too unstable to undergo ERC
2. Inclusion in any other intervention trial within the last 30 days
3. Pregnancy or lactation period

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1 participants in 2 patient groups

interventional

Experimental group

Description:

The intervention group undergoes scheduled invasive evaluation of the biliary tract with endoscopic retrograde cholangiography (ERC) with biliary interventions (i.e. therapeutic ERC) every 8 weeks for 6 months.

Treatment:

Procedure: Endoscopic retrograde cholangiography (ERC)

control

No Intervention group

Description:

The control group receives non-interventional standard of care.